Medication info
Dapaenmet Sustained Release Tablet 10/500 mg (Dapagliflozin, Metformin)

Dapaenmet Sustained Release Tablet 10/500 mg (Dapagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Pink, double-convex, oval-shaped sustained release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202301905 · Approved 2023.06.21

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching to this medication from combination therapy with dapagliflozin and metformin, this medication may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medication whole; it must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with difficulty in blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is administered to adult patients with type 2 diabetes along with dietary and exercise regimens to improve blood sugar control through the combination of dapagliflozin and metformin. It is particularly important to consult a specialist regarding the risk of cardiovascular events when using dapagliflozin in patients with cardiovascular disease or risk factors for cardiovascular disease who are not achieving adequate blood sugar control. This medication effectively assists in blood sugar control and is used in diabetes management.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching to this medication from combination therapy with dapagliflozin and metformin, this medication may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medication whole; it must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Precautions

This medication is used in the treatment of diabetes and helps in controlling blood sugar levels. Do not use this medication if there is impaired kidney function, dehydration, severe infection, or weakened cardiac function. Women who are pregnant or breastfeeding should not take this medication, nor should those with known allergy to the drug. This medication can rarely cause a serious condition called lactic acidosis, so if you experience sudden fatigue, muscle pain, difficulty breathing, or abdominal pain, consult a doctor immediately. Additionally, if used with insulin or other blood sugar-lowering agents, be cautious of symptoms of hypoglycemia and carefully monitor blood sugar levels. This medication can cause dehydration or low blood pressure, so especially elderly patients or those on diuretics should frequently check fluid status and blood pressure. Urinary infections or genital infections may arise, so seek prompt treatment if symptoms of infection occur. It is advisable to avoid alcohol consumption while on this medication, and it should be avoided in cases of impaired liver or kidney function. For surgeries or contrast imaging tests, discontinue this medication 48 hours prior to surgery, and resume only after confirming normal kidney function. This medication can lower vitamin B12 levels, so if taken long-term, regular monitoring of vitamin B12 levels is required. Special caution is required for children and the elderly, and renal function in the elderly should be frequently monitored. In case of overdose, seek immediate medical attention for proper treatment, and dialysis may be necessary depending on symptoms. This medication does not significantly affect driving or machine operation, but caution is advised as dizziness may occur. Finally, keep out of reach of children and store in the original container to maintain quality.

Side effects

Severe lactic acidosis, severe hypoglycemia, vulvovaginitis, balanitis and associated genital infections, urinary tract infections, fungal infections, hypoglycemia, decreased fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, vulvar pruritus, genital pruritus, elevated hematocrit, reduced renal creatinine clearance at the start of treatment, dyslipidemia, elevated blood creatinine at the start of treatment, elevated blood urea, weight loss, ketoacidosis, urosepsis, pyelonephritis, acute kidney injury, renal impairment, rash, diarrhea, nausea, vomiting, decreased vitamin B12, Guillain-Barré syndrome, bacterial pneumonia, sialadenitis, tendinitis, chest pain, thermal burn, wrist fracture, gastrointestinal stromal tumor, malignant neoplasm of the lung, uterine fibroids, atrial fibrillation, acute cholecystitis, upper abdominal pain, dyspepsia, abdominal discomfort, abdominal pain, gastric ulcer, irritable bowel syndrome, salivary gland mass, toothache, headache, facial paralysis, peripheral neuropathy, paresthesia, drowsiness, tremor, nasopharyngitis, pharyngitis, adenovirus conjunctivitis, shingles, pneumonia, rhinitis, elevated alanine aminotransferase, increased blood glucose, arthralgia, myalgia, myofascial pain syndrome, osteoarthritis, bone dysplasia, limb pain, periarticular inflammation, tendinitis, trigger finger, weakness, fatigue, peripheral edema, edema, pain, vitamin D deficiency, hyperglycemia, urethral syndrome, cough, hyperventilation, pruritus, palpitations, insomnia, type 2A hyperlipidemia, sensorineural hearing loss, acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air or moisture, with a recommended storage temperature between 1 and 30 degrees Celsius (room temperature). Following these storage practices will help maintain the efficacy of the medication safely.

Appearance and packaging

Appearance

Pink, double-convex, oval-shaped sustained release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.